Colorectal
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.
Clinical takeawayConsider the 14-day trifluridine-tipiracil plus bevacizumab schedule for refractory metastatic colorectal cancer to reduce toxicity, including neutropenia, while maintaining survival outcomes compared to the 28-day schedule.
What it foundThe 14-day trifluridine-tipiracil plus bevacizumab schedule showed non-inferior overall survival (HR 0.93, 95% CI 0.80-1.08) compared to the 28-day schedule, with median survival of 11.3 vs 10.3 months.
ContextThis confirms the 14-day schedule as a viable alternative to the conventional 28-day regimen, addressing toxicity concerns without compromising survival.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Sakakida T … PRABITAS investigators · The Lancet · IF 98.4 · PubMed ↗